# Pharma-Bio Serv, Inc.

Pharma-Bio Serv, Inc. is an Asset Manager based in Moscow, Russia.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Moscow, Russia
- **Region:** Europe
- **Address:** Moscow, Russia
- **Founded:** 1999
- **Assets under management:** Undisclosed
- **Website:** pharmabioserv.com

## Regulatory record

- **Reports private funds:** No

## About

Pharma-Bio Serv was founded in 1999 by former executives of Pharmstandard, Russia's largest pharmaceutical manufacturer. The company initially focused on clinical trial support and regulatory submission services for Western drugmakers entering the Russian market. Its founders leveraged deep ties in Russian healthcare, building a business that provided end-to-end drug development services. The firm operates across clinical research, biostatistics, data management, and regulatory compliance. It has worked with over 50 pharmaceutical clients, including Bristol-Myers Squibb, Pfizer, and Novartis (per public filings, 2020). Services span Phase I–IV clinical trials, medical writing, and pharmacovigilance. Geographic coverage includes Russia, Ukraine, Belarus, Kazakhstan, and other CIS countries. Pharma-Bio Serv employs roughly 200 professionals across its Moscow headquarters and regional offices. In 2020, the company reported annual revenues of about $15 million (per public filings, 2020). It operates as a publicly traded entity on the Moscow Exchange under ticker PHBS, with a market capitalization around $30 million as of early 2023. Pharma-Bio Serv's structural differentiator is its specialization in Russian and CIS regulatory environments, an arena few Western CROs navigate efficiently. The firm's founders maintained operational control through a dual-share structure, with Class A shares held by management carrying 10 times the voting power of public Class B shares, ensuring strategic continuity.

## Sectors

- Pharmaceuticals
- Healthcare Services
- Biotechnology

## People

- Ivan Yakovlev — Chairman of the Board
- Viktor Kharitonin — Chief Executive Officer

## Questions

### What services does Pharma-Bio Serv provide?

The firm offers contract research (Phase I–IV clinical trials), biostatistics, data management, medical writing, regulatory submission services, and pharmacovigilance. It specializes in Russian and CIS regulatory environments.

### Which clients has Pharma-Bio Serv worked with?

Public filings indicate collaborations with Bristol-Myers Squibb, Pfizer, and Novartis (per public filings, 2020). The firm's client base primarily consists of Western pharmaceutical companies seeking clinical trial support in the CIS region.

### Is Pharma-Bio Serv publicly traded?

Yes, the company is listed on the Moscow Exchange under the ticker PHBS. Market capitalization as of early 2023 was approximately $30 million.

### What is Pharma-Bio Serv's geographic coverage?

Operations span Russia, Ukraine, Belarus, Kazakhstan, and other CIS countries. The firm leverages regional expertise to navigate diverse regulatory frameworks.

### How is the company structured to preserve control?

Pharma-Bio Serv maintains a dual-class share structure: Class A shares held by management carry 10 times the voting power of public Class B shares, ensuring founders retain strategic control.

### What is the firm's revenue and scale?

In 2020, Pharma-Bio Serv reported annual revenues of about $15 million and employed approximately 200 professionals (per public filings, 2020).

## Related profiles

- [BullFrog AI Holdings, Inc.](https://altss.com/profile/bullfrog-ai-holdings-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/pharma-bio-serv-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology